April 1, 2010

PROTOCOL RTOG-0825
PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS BEVACIZUMAB VERSUS CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

NCI-Supplied Agent: Bevacizumab (NSC 704865; IND 7921)

Study Chair: Mark R. Gilbert, MD

REIMBURSEMENT FOR BEVACIZUMAB INFUSION SERVICES REQUIRED IN THE RTOG 0825 PROTOCOL AND DENIED BY THIRD-PARTY PAYORS

Genentech, Inc. (Genentech) has agreed to reimburse the Participating Institutions for bevacizumab infusion services required by the Protocol if that cost is not covered by a patient’s third party payer, as follows:

- Genentech has agreed to pay for claims denied by third-party payers for the cost of bevacizumab infusion services performed during the time the patient remains in the study.
- Each investigator must send a memo to Genentech to confirm the patient’s participation on RTOG-0825.
- If bevacizumab infusion services required in this protocol are denied payment by insurance, a detailed invoice along with evidence of the denied insurance claim should be submitted to Genentech for reimbursement.
- If a patient is medically indigent, this should be noted on the invoice, and the invoice should be submitted to Genentech for reimbursement.
- Numbered invoices on institutional letterhead should be sent to Genentech on a quarterly basis. Clearly mark each invoice with the RTOG protocol number (“RTOG-0825”) and the patient’s initials. Please black out the patient’s name. Please submit invoices to Genentech at the following address:

  Arthur Cannon
  Genentech, Inc.
  1 DNA Way, MS 444a
  South San Francisco, CA 94080
  Telephone: 650-225-2685
  Fax: 650-745-4153
  E-mail: cannon.arthur@gene.com